UNITY Biotechnology Inc
NASDAQ:UBX
UNITY Biotechnology Inc
NASDAQ:UBX
Price:
0.16
USD
-20.04%
Market Closed
Market Cap:
$960k
Balance Sheet
Balance Sheet Decomposition
UNITY Biotechnology Inc
UNITY Biotechnology Inc
Balance Sheet Decomposition is not available for
UNITY Biotechnology Inc
UNITY Biotechnology Inc
Balance Sheet
UNITY Biotechnology Inc
UNITY Biotechnology Inc
Currency: USD
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
89
|
7
|
15
|
37
|
18
|
33
|
13
|
20
|
8
|
|
| Cash Equivalents |
89
|
7
|
15
|
37
|
18
|
33
|
13
|
20
|
8
|
|
| Short-Term Investments |
0
|
79
|
156
|
90
|
80
|
55
|
82
|
23
|
16
|
|
| Total Receivables |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
4
|
1
|
2
|
2
|
3
|
2
|
2
|
3
|
1
|
|
| Total Current Assets |
93
|
89
|
173
|
129
|
101
|
91
|
97
|
47
|
24
|
|
| PP&E Net |
2
|
7
|
6
|
17
|
36
|
31
|
27
|
18
|
12
|
|
| PP&E Gross |
2
|
7
|
6
|
17
|
36
|
31
|
27
|
18
|
12
|
|
| Accumulated Depreciation |
0
|
1
|
4
|
6
|
10
|
12
|
13
|
9
|
9
|
|
| Long-Term Investments |
0
|
5
|
0
|
3
|
18
|
2
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
1
|
1
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
|
| Total Assets |
97
N/A
|
102
+6%
|
181
+78%
|
151
-17%
|
156
+3%
|
125
-20%
|
124
0%
|
66
-47%
|
38
-43%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
1
|
2
|
5
|
5
|
3
|
2
|
2
|
1
|
1
|
|
| Accrued Liabilities |
2
|
5
|
8
|
9
|
12
|
10
|
8
|
6
|
8
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
3
|
9
|
0
|
0
|
|
| Other Current Liabilities |
1
|
1
|
4
|
3
|
0
|
1
|
0
|
0
|
0
|
|
| Total Current Liabilities |
4
|
8
|
17
|
17
|
14
|
17
|
20
|
8
|
9
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
25
|
18
|
11
|
0
|
0
|
|
| Other Liabilities |
3
|
3
|
4
|
13
|
34
|
30
|
38
|
29
|
22
|
|
| Total Liabilities |
7
N/A
|
11
+58%
|
21
+85%
|
31
+48%
|
73
+141%
|
65
-11%
|
68
+5%
|
37
-45%
|
31
-16%
|
|
| Equity | ||||||||||
| Common Stock |
131
|
174
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
42
|
87
|
163
|
245
|
339
|
400
|
444
|
484
|
510
|
|
| Additional Paid In Capital |
1
|
4
|
325
|
367
|
422
|
460
|
501
|
513
|
517
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
90
N/A
|
91
+1%
|
161
+77%
|
121
-25%
|
83
-31%
|
60
-28%
|
56
-6%
|
28
-49%
|
6
-77%
|
|
| Total Liabilities & Equity |
97
N/A
|
102
+6%
|
181
+78%
|
151
-17%
|
156
+3%
|
125
-20%
|
124
0%
|
66
-47%
|
38
-43%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
4
|
4
|
4
|
5
|
5
|
6
|
14
|
17
|
17
|
|
Switch to:
Switch to:
See Also
Discover More
